self-replicating (Pluripotent stem) cells evaluation in patients of hepatocellular cancer
Not Applicable
- Conditions
- Health Condition 1: C220- Liver cell carcinoma
- Registration Number
- CTRI/2019/11/022000
- Lead Sponsor
- Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
CT/MRI scan
TNM stage & Grade, Vascular invasion present/absent
Liver Function Test (LFT): Total bilirubin, AST(SGOT)/ALT(SGPT), Alkaline phosphatase and gamma-GGT tests as per the institutional limit.
At least one measurable lesion as defined by RECIST criteria
Tumour size and tumour number.
Exclusion Criteria
Hepatitis, fibrosis, cirrhotic, fatty liver patients, other chronic liver diseases and alcoholic patients should be excluded for normal liver.
No PET-CT scan 15 days prior to sample collection.
No blood transfusion 30 days prior to sample collection.
No concomitant radiation therapy or other systemic cancer therapies.
Previous history of any malignancy none.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establishment, characterization and validation of human hepatocellular carcinoma induced pluripotent stem cells and normal liver induced pluripotent stem cells.Timepoint: 2 Years
- Secondary Outcome Measures
Name Time Method -To monitor the realâ??time effects of an imaging probe Quantum dot NP, and tracking the microtubules and microtubules motor proteins in the above mentioned stem cells. <br/ ><br>-Assessment of the efficacy of nanoformulations in HCC iPSCs using therapeutic drugs <br/ ><br>and its potential molecular targets. <br/ ><br>Timepoint: 2 Years